Boston Pharma Appoints Santiago Arroyo, M.D., Ph.D., As Chief Medical Officer And Constantine Chinoporos, As Chief Business Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals, a new fully integrated drug development company offering an innovative alternative model for drug development commercializiation, today announced the appointment of Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer and Constantine Chinoporos, as Chief Business Officer. Both will work with senior leadership at the company to identify and partner with academic, biotechnology and biopharmaceutical groups to acquire clinical assets at various stages of their development and bring them to market.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.